Prolonged release oxycodone and naloxone treatment counteracts opioid-induced constipation in patients with severe pain compared to previous analgesic treatment

References

• Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-333
   PubMed Web of Science ®Google Scholar
• Blyth FM, March LM, Brnabic AJM, Cousins MJ. Chronic pain and frequent use of health care. Pain 2004;111:51-8
   PubMed Web of Science ®Google Scholar
• WHO. Cancer Pain Relief 2nd edition. With a guide to opioid availability. World Health Organization. Geneva 1996. ISBN 92 4 154482 1
   Google Scholar
• Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 2005;293:3043-52
   PubMed Web of Science ®Google Scholar
• Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage 2003;26:1026-48
   PubMed Web of Science ®Google Scholar
• Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001;322:1154-8
   PubMed Web of Science ®Google Scholar
• Drewes AM, Jensen RD, Nielsen LM, et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol 2012;75:60-78
   Web of Science ®Google Scholar
• Coluzzi F, Pappagallo M. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol 2005;71:425-33
   PubMedGoogle Scholar
• Brock C, Olesen SS, Olesen AE, et al. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs 2012;72:1847-65
   PubMed Web of Science ®Google Scholar
• Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med 2009;10:35-42
   PubMed Web of Science ®Google Scholar
• Diego L, Atayee R, Helmons P, et al. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs 2011;20:1047-56
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJA, Haak van den P, Klok RM, et al. Quality of life in relation to constipation among opioid users. J Med Econ 2010;13:129-35
   PubMedGoogle Scholar
• Coyne KS, LoCasale RJ, Datto CJ, et al. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. ClinicoEconomics Outcomes Res 2014;6:269-81
   PubMedGoogle Scholar
• Abramowitz L, Beziaud N, Labreze L, et al. Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J Med Econ 2013;16:1423-33
   PubMedGoogle Scholar
• Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007;61:1181-7
   PubMed Web of Science ®Google Scholar
• McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003;4:231-56
   PubMed Web of Science ®Google Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(5ASuppl):11-18S
   Web of Science ®Google Scholar
• Mancini IL, Bruera E. Constipation in advanced cancer patients. Support Care Cancer 1998;6:356-64
   PubMed Web of Science ®Google Scholar
• Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 2012;50:360-7
   PubMed Web of Science ®Google Scholar
• Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144-54
   PubMed Web of Science ®Google Scholar
• Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008;24:3503-12
   PubMed Web of Science ®Google Scholar
• Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010;64:763-74
   PubMed Web of Science ®Google Scholar
• Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomized controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64
   PubMed Web of Science ®Google Scholar
• Lowenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomized controlled trial. Expert Opin Pharmacother 2009;10:531-43
   PubMed Web of Science ®Google Scholar
• Lowenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomized, double-blind clinical trials. BMC Clin Pharmacol 2010;10:12
   PubMedGoogle Scholar
• Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50-60
   PubMed Web of Science ®Google Scholar
• Kuusniemi K, Zollner J, Sjovall S, et al. Prolonged-release oxycodone/naloxone in postoperative pain management: from a randomized clinical trial to usual clinical practice. J Int Med Res 2012;40:1775-93
   PubMed Web of Science ®Google Scholar
• Hermanns K, Junker U, Nolte T. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain – results from a large observational study. Expert Opin Pharmacother 2012;13:299-311
   PubMed Web of Science ®Google Scholar
• Gatti A, Casali M, Lazzari M, et al. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation. Adv Ther 2013;30:41-59
   PubMed Web of Science ®Google Scholar
• Schutter U, Grunert S, Meyer C, et al. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin 2010;26:1377-87
   PubMed Web of Science ®Google Scholar
• Rentz AM, Yu R, Muller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009;12:371-83
   PubMedGoogle Scholar
• Rentz AM, van Hanswijck de Jonge P, Leyendecker P, Hopp M. Observational, nonintervention, multicenter study for validation of the Bowel Function Index for constipation in European countries. Curr Med Res Opin 2011;27:35-44
   PubMed Web of Science ®Google Scholar
• Ueberall MA, Muller-Lissner S, Buschmann-Kramm C, Bosse B. The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res 2011;39:41-50
   PubMed Web of Science ®Google Scholar
• Chang JY, Locke GR, Schleck CD, et al. Risk factors for chronic constipation and a possible role of analgesics. Neurogastroenterol Motil 2007;19:905-11
   PubMed Web of Science ®Google Scholar
• Fosnes GS, Lydersen S, Farup PG. Constipation and diarrhoea – common adverse drug reactions? A cross sectional study in the general population. BMC Clin Pharmacol 2011;11:2
   PubMedGoogle Scholar
• Langley PC, Patkar AD, Boswell KA, et al. Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain. Curr Med Res Opin 2010;26:239-51
   PubMed Web of Science ®Google Scholar
• Clark K, Lam LT, Agar M, et al. The impact of opioids, anticholinergic medications and disease progression on the prescription of laxatives in hospitalized palliative care patients: a retrospective analysis. Palliat Med 2010;24:410-18
   PubMed Web of Science ®Google Scholar
• van Dongen VC, Vanelderen PJ, Koopmans-Klein G, et al. Patient preference with respect to QoL and reduction in opioid-induced constipation (OIC) after treatment with prolonged-release (PR) oxycodone/naloxone compared with previous analgesic therapy [PREFER study]. Int J Clin Pract 2014;68:1364-75
   PubMed Web of Science ®Google Scholar
• Ueberall MA, Mueller-Schwefe GH. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations. Curr Med Res Opin 2015;31:1413-29
   PubMed Web of Science ®Google Scholar
• Müller-Lissner S. Opioid-induced constipation – mechanisms, relevance and management. Eur Gastroenterol Hepatol Rev 2010;6:54-7
   Google Scholar
• Leppert W. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review. Adv Ther 2010;27:714-30
   PubMed Web of Science ®Google Scholar
• McCarberg BH, Nicholson BD, Todd KH, et al. The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey. Am J Ther 2008;15:312-20
   PubMed Web of Science ®Google Scholar
• Khan SA, Goyyal C, Chandel C, Rafi M. Knowledge, attitudes, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: an observational study. J Nat Sci Biol Med 2013;4:191-6
   PubMedGoogle Scholar